Back To “Hurry Up And Wait” With Lexicon (NASDAQ:LXRX)
The frustrating reality for a lot of biotech shareholders is that while these stocks can enjoy strong runs on thesis-altering data announcements, a lot of time as a biotech investor is spent waiting. Such is […]
